These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 38042909)

  • 1. Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives.
    Liu J; Pan S; Wang X; Liu Z; Zhang Y
    Eur J Med Res; 2023 Dec; 28(1):553. PubMed ID: 38042909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Glycation End Products and Their Effect on Vascular Complications in Type 2 Diabetes Mellitus.
    Lee J; Yun JS; Ko SH
    Nutrients; 2022 Jul; 14(15):. PubMed ID: 35956261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
    Khalid M; Petroianu G; Adem A
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes.
    Yang P; Feng J; Peng Q; Liu X; Fan Z
    Oxid Med Cell Longev; 2019; 2019():9570616. PubMed ID: 31885827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention.
    Yamagishi SI
    Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
    Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
    Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of advanced glycation end products (AGEs) signaling in coronary artery disease.
    Kosmopoulos M; Drekolias D; Zavras PD; Piperi C; Papavassiliou AG
    Biochim Biophys Acta Mol Basis Dis; 2019 Mar; 1865(3):611-619. PubMed ID: 30611860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of Advanced Glycation End Products With Cardiovascular Disease in Menopausal Women.
    Pertynska-Marczewska M; Merhi Z
    Reprod Sci; 2015 Jul; 22(7):774-82. PubMed ID: 25228634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revisiting Methodologies for In Vitro Preparations of Advanced Glycation End Products.
    Sahi AK; Verma P; Varshney N; Gundu S; Mahto SK
    Appl Biochem Biotechnol; 2022 Jun; 194(6):2831-2855. PubMed ID: 35257316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
    Yamagishi S; Matsui T; Nakamura K
    Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of advanced glycation end products on vascular smooth muscle cells under diabetic atherosclerosis.
    Mao L; Yin R; Yang L; Zhao D
    Front Endocrinol (Lausanne); 2022; 13():983723. PubMed ID: 36120471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
    Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
    Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease.
    Pinto RS; Minanni CA; de Araújo Lira AL; Passarelli M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
    Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
    Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end products (AGEs) and cardiovascular dysfunction: focus on high molecular weight AGEs.
    Deluyker D; Evens L; Bito V
    Amino Acids; 2017 Sep; 49(9):1535-1541. PubMed ID: 28710551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decoding the role of aldosterone in glycation-induced diabetic complications.
    Apte M; Zambre S; Pisar P; Roy B; Tupe R
    Biochem Biophys Res Commun; 2024 Aug; 721():150107. PubMed ID: 38781658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smooth muscle cell pathophysiology and advanced glycation end products (AGEs).
    Yamagishi S; Matsui T
    Curr Drug Targets; 2010 Jul; 11(7):875-81. PubMed ID: 20412043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus.
    Hori O; Yan SD; Ogawa S; Kuwabara K; Matsumoto M; Stern D; Schmidt AM
    Nephrol Dial Transplant; 1996; 11 Suppl 5():13-6. PubMed ID: 9044300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AGE/RAGE in diabetic kidney disease and ageing kidney.
    Wu XQ; Zhang DD; Wang YN; Tan YQ; Yu XY; Zhao YY
    Free Radic Biol Med; 2021 Aug; 171():260-271. PubMed ID: 34019934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic targeting of advanced glycation end-products in age-related diseases.
    Rowan S; Bejarano E; Taylor A
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3631-3643. PubMed ID: 30279139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.